Your Search for ag1343 or nelfinavir matched 1000 Documents (Page 1 of 34).
You may want to refine your search. Results Indexed by relevance.
Abstract: The use of the protease inhibitor nelfinavir (Viracept) has been associated with diarrhea. Some community-based clinics report that upwards of 80% of their clients who are using nelfinavir experience this side effect to varying degrees. While this figure is higher than what has been reported in studies, it underscores ...
http://www.aegis.org/pubs/projinform/2003/pi030116.html
File Name: pi030116.html, Size: 8KB, Last Modified: Thursday, May 21, 2009 at 9:30:31 PM
Abstract: A study from Rolf van Heeswijk and colleagues from the Ottawa Health Research Institute in Canada evaluated the pharmacokinetics and its active metabolite M8 during pregnancy and post partum. ...
http://www.aegis.org/pubs/i-base/2004/ib040504-04.html
File Name: ib040504-04.html, Size: 9KB, Last Modified: Thursday, May 21, 2009 at 9:28:33 PM
Abstract: Pravastatin and nelfinavir coadministration reduces pravastatin plasma levels. According to a study from the United States, "Nelfinavir, an HIV protease inhibitor with numerous drug-drug interactions, is associated with dyslipidemia. Pravastatin is the preferred statin prescribed for HIV-associated dyslipidemia." ...
http://www.aegis.org/pubs/aidswkly/2006/aw060515.html
File Name: aw060515.html, Size: 10KB, Last Modified: Thursday, May 21, 2009 at 9:26:49 PM
Abstract: Genetic variants may predict virologic failure and/or emergence of drug-resistant HIV. "Efavirenz and nelfinavir are metabolized by cytochrome P-450 (CYP) 2B6 and CYP2C19, respectively, with some involvement by CYP3A. Nelfinavir is a substrate for P-glycoprotein, which is encoded by MDR1. The present study examined ass ...
http://www.aegis.org/pubs/aidswkly/2006/aw060104.html
File Name: aw060104.html, Size: 11KB, Last Modified: Thursday, May 21, 2009 at 9:26:48 PM
Abstract: The promising new HIV protease inhibitor AG1343 is effective and well tolerated at all doses studied in Phase II clinical trials. The drug, developed by Agouron Pharmaceuticals and Japan Tobacco Inc. under the trade name Viracept, has been the subject of intense interest since the 1994 2nd National Conference on Human ...
http://www.aegis.org/pubs/aidswkly/1995/aw951008.html
File Name: aw951008.html, Size: 8KB, Last Modified: Monday, January 05, 2009 at 10:05:20 PM
Abstract: HIV patients who suffer from severe rashes after nelfinavir treatment can be desensitized to the protease inhibitor as with other allergens, researchers in Georgia report. ...
http://www.aegis.org/pubs/aidswkly/2001/aw010612.html
File Name: aw010612.html, Size: 8KB, Last Modified: Monday, January 05, 2009 at 10:02:12 PM
Abstract: The protease inhibitor nelfinavir interferes with fat-cell development, which could be a cause for wasting syndrome. ...
http://www.aegis.org/pubs/aidswkly/2001/aw010303.html
File Name: aw010303.html, Size: 9KB, Last Modified: Monday, January 05, 2009 at 10:02:10 PM
Abstract: AEGIS, AIDS Daily Summary, HIV, AIDS, HIV infection, opportunistic infections. var gaJsHost = (https: = document.location.protocol) ? "https:ssl. : "http:www. document.write(unescape(3Cscript src= + gaJsHost + "google-analytics.com/ga.js' type=text/javascript'3E%3C/script%3E"ion" CONTENT= Agouron Pha ...
http://www.aegis.org/news/ads/1994/ad941878.html
File Name: ad941878.html, Size: 10KB, Last Modified: Sunday, January 04, 2009 at 6:49:03 PM
Abstract: The nelfinavir ONLINE TDM assay* shows good precision, high analytical sensitivity, and comparability to chromatography-based reference methods. The fully automated immunoassay offers fast turnaround time (approx. 10 min), low sample volume (3 ml), and no sample pre-treatment. ...
http://www.aegis.org/conferences/iac/2006/tupe0101.html
File Name: tupe0101.html, Size: 9KB, Last Modified: Wednesday, April 23, 2008 at 8:00:00 AM
Abstract: Catie, AEGiS, HIV, AIDS, 5th International Workshop on Pharmacology, drug absorption, drug interactions, nukes, protease inhibitors, (PIs) non-nukes, NNRTIs, non-nucleoside reverse transcriptase inhibitors, fusion inhibitors, salvage therapy, P450 enzymes, pregnancy, Nelfinavir levels, Nelfinavir, Viracept. ...
http://www.aegis.org/pubs/catie/2004/cate14205.html
File Name: cate14205.html, Size: 9KB, Last Modified: Tuesday, March 06, 2007 at 6:45:00 PM
Abstract: This article is based on information presented at the 4th Conference on Retroviruses and Opportunistic Infections in Washington ...
http://www.aegis.org/pubs/catie/1997/cate7605.html
File Name: cate7605.html, Size: 8KB, Last Modified: Tuesday, March 06, 2007 at 6:43:25 PM
Abstract: The Food and Drug Administration today approved two HIV protease inhibitors -- some of the most powerful medicines against the infection -- for use in treating children. Nelfinavir received its initial approval today -- including information on use in both adults and children -- approximately 3 months after its applica ...
http://www.aegis.org/news/fda/1997/fd970301.html
File Name: fd970301.html, Size: 9KB, Last Modified: Tuesday, March 06, 2007 at 5:40:16 PM
Abstract: The use of protease inhibitor regimens is associated with increased levels of triglycerides and "bad" cholesterol (LDL or low density lipoprotein). Doctors may give their patients taking PIs statins, a group of drugs that lower the level of fatty substances (lipids) in the blood. Two popular statins are Zocor (simvasta ...
http://www.aegis.org/news/catie/2000/cate-n20000904.html
File Name: cate-n20000904.html, Size: 7KB, Last Modified: Monday, January 08, 2007 at 11:20:07 PM
Abstract: a. Simple Facts Sheet. from the. AIDS Treatment Data Network. nelfinavir (Viracept). Nelfinavir (trade name Viracept) is one of a new class of anti-HIV drugs called. protease inhibitors. These drugs work by blocking a part of HIV called protease. When protease is blocked, HIV makes copies of itself that can't i ...
http://www.aegis.org/factshts/network/simple/nelf.html
File Name: nelf.html, Size: 8KB, Last Modified: Sunday, August 20, 2006 at 9:21:18 PM
Abstract: Steady state pharmacokinetics of nelfinavir 625mg tablet showed bioequivalence with the 250mg tablet and comparable safety and efficacy profiles in nelfinavir-treatment-experienced HIV patients. ...
http://www.aegis.org/conferences/lipo/2005/100.html
File Name: 100.html, Size: 6KB, Last Modified: Monday, November 14, 2005 at 6:29:23 AM
Abstract: Although the study's small, retrospective and limited by relatively late first on-treatment viral load sampling the reduced rate of viral decay in pregnant women taking a nelfinavir-containing regimen suggest that the PK data are of clinical importance. ...
http://www.aegis.org/conferences/bhiva/2005/p43.html
File Name: p43.html, Size: 5KB, Last Modified: Wednesday, April 20, 2005 at 8:12:04 PM
Abstract: A study was conducted to assess the role of antiretroviral adherence and HIV viral load on subsequent development of HIV viral resistance. Eleven HIV-infected patients were enrolled into this study, all patients were prescribed nelfinavir in combination with at least two other antiretrovirals (ARV). Four patients were ...
http://www.aegis.org/conferences/iac/2004/b12299.html
File Name: b12299.html, Size: 6KB, Last Modified: Monday, July 12, 2004 at 6:29:23 AM
Abstract: BACKGROUND: To compare tolerance and immuno-virological efficacy of low-dose ritonavir (RTV)/ saquinavir (SQV) vs nelfinavir. METHODS: From our prospective cohort we selected RTV/SQV or nelfinavir therapeutic sequences, beginning on 01/01/2000. ...
http://www.aegis.org/conferences/iac/2004/tupeb4550.html
File Name: tupeb4550.html, Size: 6KB, Last Modified: Monday, July 12, 2004 at 6:29:23 AM
Abstract: Bayesian Networks were very informative for subtype-dependent nelfinavir resistance pathways. We found different frequencies of mutations in patients failing nelfinavir when comparing subtype B and G, while some new mutations were identified. Whether these differences are only dependent on the genetic background or whe ...
http://www.aegis.org/conferences/hivdrw/2004/103.html
File Name: 103.html, Size: 7KB, Last Modified: Wednesday, June 09, 2004 at 6:29:23 AM
Abstract: Elevated doses of nelfinavir further reduced the replicative fitness of the D30N virus. This virus was hypersusceptible to amprenavir in the absence of the N88S mutation. In vivo studies with 250 mg of nelfinavir added to a second PI regimen will aid to understand how to preserve these replicative impaired viruses, and ...
http://www.aegis.org/conferences/hivdrw/2004/57.html
File Name: 57.html, Size: 6KB, Last Modified: Wednesday, June 09, 2004 at 6:29:23 AM
Abstract: HAART, AIDS, HIV, AIDS / HIV Treatment Information, Project Inform, Protease Inhibitors, AZT, Health, AIDS Activism, Project Inform Perspective, Non Profit Organizations, HIV Services, SIDA. Important note: Information in this article was accurate in April 2000. The state of the art may have changed since the publi ...
http://www.aegis.org/pubs/projinform/2000/pi000403.html
File Name: pi000403.html, Size: 11KB, Last Modified: Wednesday, February 11, 2004 at 11:11:20 PM
Abstract: AEGIS, 8th EUROPEAN CONFERENCE ON CLINIC ASPECTS AND TREATMENT OF HIV - INFECTION. Abstract Form. REFERENCE NUMBER : 251. ECCATH ID : P162. 8th EUROPEAN CONFERENCE ON CLINIC ASPECTS AND TREATMENT OF HIV - INFECTION. Location of research or project (country). USA. Thematic Areas:. 7.1. PK and pharmacodynamics. 3.3. ...
http://www.aegis.org/conferences/eacs/2001/posters/215.html
File Name: 215.html, Size: 8KB, Last Modified: Monday, December 29, 2003 at 10:30:23 PM
Abstract: In conclusion, the occurrence of the specific nelfinavir genotypic resistance profile is infrequent among both nelfinavir-naïve and nelfinavir-experienced patients. Cross-resistance between nelfinavrir and other protease inhibitors may be limited also in patients who experienced prior long-term antiretroviral therapy, ...
http://www.aegis.org/conferences/hiv-glasgow/2002/p238.html
File Name: p238.html, Size: 6KB, Last Modified: Sunday, November 17, 2002 at 8:12:04 PM
Abstract: Management of nelfinavir-related diarrhoea E NEGREDO, G SIRERA, J PUIG, CR FUMAZ, GEL S, B CLOTET. Lluita contra la SIDA Found. Hosp. Germans Trias i Pujol. Barcelona. Spain . <p><b>BACKGROUND:</b> Nelfinavir-related diarrhoea is the most common adverse event in patients who begin nelfinavir-based combination regimen ...
http://www.aegis.org/conferences/iac/2002/tupeb4526.html
File Name: tupeb4526.html, Size: 7KB, Last Modified: Monday, July 08, 2002 at 6:29:23 AM
Abstract: <p><b>BACKGROUND:</b> Prior studies have reported the impact of Nelfinavir containing antiretroviral combinations in profoundly suppressing HIV replication. There is little data however, involving treatment experienced individuals with advanced disease. </p> <p><b>METHODS:</b> We retrospectively analyzed the records ...
http://www.aegis.org/conferences/iac/2002/b10192.html
File Name: b10192.html, Size: 7KB, Last Modified: Monday, July 08, 2002 at 6:29:23 AM
Abstract: High-level nelfinavir resistance with the D30N mutation was present at VF in 39% of subjects. Nelfinavir failure was frequently associated with reduced susceptibility to nelfinavir and the emergence of ‘secondary’ mutations without PPM. Continued nelfinavir use after VF selected for progressively increasing nelfinavir ...
http://www.aegis.org/conferences/hivdrw/2002/144.html
File Name: 144.html, Size: 7KB, Last Modified: Wednesday, July 03, 2002 at 6:29:23 AM
Abstract: In addition to the large difference in the development of primary PI resistance observed in this blinded, comparative study of LPV/r- and nelfinavir-based ARV, the emergence of secondary mutations either with or without primary resistance occurred more commonly in nelfinavir-treated subjects than in LPV/r-treated subje ...
http://www.aegis.org/conferences/hivdrw/2002/145.html
File Name: 145.html, Size: 6KB, Last Modified: Wednesday, July 03, 2002 at 6:29:23 AM
Abstract: Although the same major protease mutations develop in subtype B and C pts failing PI therapy, the rates at which mutational pathways develop differ for certain drugs. This may be due to the impact of baseline polymorphisms on resistance and fitness when mutations develop. Knowledge of these differences may have importa ...
http://www.aegis.org/conferences/hivdrw/2002/34.html
File Name: 34.html, Size: 6KB, Last Modified: Wednesday, July 03, 2002 at 6:29:23 AM
Abstract: In a standardized protocol, in vitro selection of resistant HIV was much slower with TMC114 as compared to amprenavir, nelfinavir or lopinavir. While virus capable of replicating in micromolar levels of amprenavir, nelfinavir or lopinavir was readily selected, the selection concentration of TMC114 could not be raised a ...
http://www.aegis.org/conferences/hivdrw/2002/5.html
File Name: 5.html, Size: 7KB, Last Modified: Wednesday, July 03, 2002 at 6:29:23 AM
Abstract: La RED de Información del SIDA. Nelfinavir (Viracept). Actualizado, junio de 1997. Nelfinavir (nombre de marca Viracept, anteriormente conocido como AG-1343) pertenece a un nuevo grupo de medicamentos contra elVIH. llamados. inhibidores de proteasa. Estos medicamentos funcionan bloqueando una parte ...
http://www.aegis.org/factshts/network/lared/simple/nelf.html
File Name: nelf.html, Size: 8KB, Last Modified: Tuesday, April 23, 2002 at 7:57:59 PM